Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026 ROCKVILLE, Md., October 19, 2026 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializ
How this was made
The 30-second read
Why it matters
The filing is a standard earnings‑release notice with no new financial data, so immediate price impact is expected to be muted.
Market read
The notice primarily informs shareholders of the upcoming earnings call; it does not provide new financial metrics.
What to watch
Potential hidden guidance or surprise in the upcoming earnings could move the stock sharply; investors should monitor analyst expectations.
Background
Supernus Pharmaceuticals (NASDAQ: SUPN) filed an 8‑K announcing the date and time of its Q3 2026 earnings release and conference call.
Ticker impact
Company announced it will release Q3 2026 results and host a conference call on Oct 29, 2026.
likely neutral as market awaits the actual earnings numbers
No new financial metrics were disclosed; only the timing of the upcoming results was provided.
Market effects
Minimal impact on the broader biotech sector; the announcement is routine.
Limited to investors tracking US biotech earnings calendar.
Low; only relevant to shareholders of SUPN.
Counterpoint
If the market over‑reacts to the call announcement, a short position could be considered ahead of the actual results.
Key entities
- companySupernus Pharmaceuticals
US‑listed biopharma focused on CNS disorders.
- personJack Khattar
President and CEO of Supernus.
- personTim Dec
Senior Vice President and CFO of Supernus.
